HMGN2 peptides and related molecules that selectively home...

Details HMGN2 peptides and related molecules that selectively home... HMGN2 peptides and related molecules that selectively home...

2003-03-20

2009-06-09

Helms, Larry R. (Department: 1642)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

C530S324000

Reexamination Certificate

active

07544767

ABSTRACT:
The present invention provides a conjugate which contains a therapeutic moiety linked to a homing molecule that selectively homes to tumor blood vessels and tumor cells and that specifically binds the receptor bound by peptide KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK (SEQ ID NO: 9). Methods of directing a conjugate of the invention to tumor blood vessels and tumor cells and of using a conjugate to treat cancer also are provided.

REFERENCES:
patent: 5536814 (1996-07-01), Ruoslahti et al.
patent: 5622699 (1997-04-01), Ruoslahti et al.
patent: 6468758 (2002-10-01), Benson et al.
patent: 2003/0194754 (2003-10-01), Miller et al.
patent: 0 135 277 (1985-03-01), None
patent: 0 410 537 (1991-01-01), None
patent: 0 639 584 (1995-02-01), None
patent: WO 92/00091 (1992-01-01), None
patent: WO 92/03461 (1992-03-01), None
patent: WO 92/06191 (1992-04-01), None
patent: WO 94/11003 (1994-05-01), None
patent: WO 95/14714 (1995-06-01), None
patent: WO 97/10507 (1997-03-01), None
patent: WO 97/19954 (1997-06-01), None
patent: WO/01/75067 (2001-10-01), None
Mathews and Van Holde, Biochemistry, 1996, pp. 165-171.
Burgess et al, Journal of Cell biology, vol. 111, p. 2129-2138, 1990.
Lin et al Biochemistry USA, vol. 14, p. 1559-1563, 1975.
Asai et al., FEBS, vol. 510, p. 206-210, Apr. 2002.
Porkka et al., PNAS, vol. 99, p. 7444-7449, May 2002.
Li et al., (Proc. Natl. Acad. Sci: USA 77:3211-3214, 1980.
Essler et al., PNAS, vol. 99., p. 2252-2257, Feb. 19, 2002.
Xu et al., “Inhibition of DNA replication and induction of S Phase cell cycle arrest by G-rich oligonucleotides,”J. Biol. Chem. 276:43221-43230 (2001).
Alfonso et al., “The footprint of chromosomal proteins HMG-14 and HMG-17 on chromatin subunits,”J. Mol. Biol. 236:189-198 (1994).
Arap et al., “Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model,”Science279:377-380 (1998).
Arap et al., “Targeting the prostate for destruction through a vascular address,”Proc. Natl. Acad. Sci. USA99:1527-1531 (2002).
Asahara et al., “Isolation of putative progenitor endothelial cells for angiogenesis,”Science275:864-967 (1997).
Asahara et al., “VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells,”EMBO J. 18:3964-3972 (1999).
Baillie et al., “Tumor vasculature—a potential therapeutic target,”British J. Cancer72:257-267 (1995).
Bergers et al., “Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis,”Nature Cell Biol. 2:737-744 (2000).
Bicknell, “Vascular targeting and the inhibition of angiogenesis,”Annals of Oncology5(Supp. 4): S45-S50 (1994).
Borer et al, “Major nucleolar proteins shuttle between nucleus and cytoplasm,”Cell56:379-390 (1989).
Brooks et al., “Integrin αvβ3antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels,”Cell79:1157-1164 (1994).
Burioni et al, “Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro,”Proc. Natl. Acad. Sci. USA91:355-359 (1994).
Burrows and Thorpe, “Vascular targeting—a new approach to the therapy of solid tumors,”Pharmac. Ther. 64:155-174 (1994).
Bustin, “Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins,”Mol. Cell Biol. 19:5237-5246 (1999).
Bustin and Reeves, “High-mobility-group chromosomal proteins: Architectural components that facilitate chromatin function,”Prog. Nucl. Acid. Res. Mol. Biol. 54:35-100 (1996).
Carson-Walter et al., “Cell surface tumor endothelial markers are conserved in mice and humans,”Cancer Res. 61:6649-6655 (2001).
Cattani et al., “Cloning and characterization of human recombinant antibody Fab fragments specific for types 1 and 2Herpes simplexvirus,”Microbiologica18:135-142 (1995).
Curnis et al., “Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13),”Nature Biotechnology18:1185-1190 (2000).
Davidoff et al., “Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice,”Clin. Cancer Res. 7:2780-2879 (2001).
Deng et al., “Internalization of anti-nucleolin antibody into viable Hep-2 cells,”Mol. Biol. Rep. 23:191-195 (1996).
Ding et al., “Alleviation of histone H1-mediated transcriptional repression and chromatin compaction by the acidic activation region in chromosomal protein HMG-14,”Mol. Cell Biol. 17:5843-5855 (1997).
Dvorak et al., “Structure of solid tumors and their vasculature: Implications for therapy with monoclonal antibodies,”Cancer Cells3:77-85 (1991).
Fages et al., “Regulation of cell migration by amphoterin,”J. Cell Science113:611-620 (2000).
Fawell et al., “Tat-mediated delivery of heterologous proteins into cells,”Proc. Natl.Acad. Sci. USA91:664-668 (1994).
Folkman, “Addressing tumor blood vessels,”Nat. Biotech. 15:510 (1997).
Friedlander et al., “Definition of two angiogenic pathways by distinct αvintegrins,”Science270:1500-1502 (1995).
Furka et al., “General method for rapid synthesis of multicomponent peptide mixtures,”Intl. J. Peptide Protein Res. 37:487-493 (1991).
Gallouzi and Steitz, “Delineation of mRNA export pathways by the use of cell-permeable peptides,”Science294:1895-1901 (2001).
Geier et al., “Fate of bacteriophage lambda in non-immune germ-free mice,”Nature246:221-223 (1973).
GenBank Accession No. CAB46820 Non-histone chromosomal protein HMG-17 (Canis familiaris).
GenBank Accession No. NSBOH7 Non-histone chromosomal protein HMG-17—bovine.
GenBank Accession No. S11349 Non-histone chromosomal protein HMG-17—rat.
Gingrich et al., “Metastatic prostate cancer in a transgenic mouse,”Cancer Res. 56:4096-4102 (1996).
Ginisty et al., “Structure and functions of nucleolin,”J. Cell Sci. 112:761-772 (1999).
Goetz et al., “Lu-ECAM-1-mediated adhesion of melanoma cells to endothelium under conditions of flow,”Int. J. Cancer65:192-199 (1996).
Goodson et al., “High-affinity urokinase receptor antagonists identified with bacteriophage peptide display,”Proc. Natl. Acad. Sci. USA91:7129-7133 (1994).
Hammes et al., “Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization,”Nature Medicine2:529-533 (1996).
Hanahan, “Signaling vascular morphogenesis and maintenance,”Science277:48-50 (1997).
Hanahan and Folkman, “Patterns and emerging mechanisms of the angiogenic swithc during tumorigenesis,”Cell86:353-364 (1996).
Hanahan and Weinberg, “The hallmarks of cancer,”Cell100:57-70 (2000).
Hart et al., “Cell Binding and internalization by filamentous phage displaying a cyclic Arg-Gly-Asp-containing peptide,”J. Biol Chem. 269(17):12468-12474 (1994).
Healy et al., “Peptide ligands for integrin αvβ3selected from random phage display libraries,”Biochem. 34:3948-3955 (1995).
Holash et al., “Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF,”Science284:1994-1998 (1999).
Hori et al., “The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin,”J. Biol. Chem. 270:25752-25761.
Hornik and Hadas, “Self-encoded, highly condensed solid phase-supported peptide library for identification of ligand-specific peptides,”Chem. Abstracts121: Abstract 77731p, React. Polym. 22(3):213-220 (1994).
Hovanessian et al., “The cell-surface-expressed nucleolin is associated with the actin cytoske

Affiliated with

Also associated with

Rating

HMGN2 peptides and related molecules that selectively home... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HMGN2 peptides and related molecules that selectively home..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HMGN2 peptides and related molecules that selectively home... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4117040